Clinical Trials
41 trialsTRIDENT-1
Turning Point Therapeutics, Inc.
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Molecular Partners AG
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Perspective Therapeutics
BRAVESST2
Crinetics Pharmaceuticals Inc.
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Teclison Ltd.
LIBRETTO-001
Eli Lilly and Company
STARTRK-NG
Hoffmann-La Roche
MK-6070-001
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy Males
YourChoice Therapeutics, Inc.
Spencer
Enterome
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Chimeric Therapeutics
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
IDEAYA Biosciences
LIBRETTO-121
Eli Lilly and Company
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phanes Therapeutics
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
Vyriad, Inc.
Open-label Study of Surufatinib in Japanese Patients
Hutchmed
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
ARROW
Hoffmann-La Roche
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
Crinetics Pharmaceuticals Inc.
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Purple Biotech Ltd.
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe, Inc.
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Hutchmed
Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation
Shanghai Henlius Biotech
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
Ipsen
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Novartis
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Tarveda Therapeutics
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
Daiichi Sankyo
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
Ipsen
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
Arbutus Biopharma Corporation
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.